Roles of pathologists in molecular targeted cancer therapy

Journal of Cellular and Molecular Medicine

Volumn 13, Issue 11-12, 2009, Pages 4286-4290

  Osamura, Robert Y ^a  

^a TOKAI UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ARTICLE; GENETICS; HUMAN; MANPOWER; METABOLISM; NEOPLASM; PATHOLOGY; PHYSICIAN ATTITUDE; SIGNAL TRANSDUCTION; TUMOR GENE;

GENES, NEOPLASM; HUMANS; NEOPLASMS; PATHOLOGY; PHYSICIAN'S ROLE; SIGNAL TRANSDUCTION;

EID: 77951179471     PISSN: 15821838     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1582-4934.2009.00960.x     Document Type: Article

References (33)

1. Wolff AC, Hammond ME, Schwartz JN. American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer. Arch Pathol Lab Med. 2007, 131:18-43.
2. Hofmann M, Stoss O, Gaiser T. Central HER2 IHC and FISH analysis in a trastuzumab (Herceptin) phase II monotherapy study: assessment of test sensitivity and impact of chromosome 17 polysomy. J Clin Pathol. 2008, 61:89-94.
3. Kobayashi S, Boggon TJ, Dayaram T. EGFR mutation and resistance of non-small-cell lung cancer to gefitinib. N Engl J Med. 2005, 352:786-92.
4. Lynch TJ, Bell DW, Sordella R. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N Engl J Med. 2004, 350:2129-39.
5. Sasaki H, Endo K, Konishi A. EGFR Mutation status in Japanese lung cancer patients: genotyping analysis using LightCycler. Clin Cancer Res. 2005, 11:2924-9.
6. Yu J, Kane S, Wu J. Mutation-specific antibodies for the detection of EGFR mutations in non-small-cell lung cancer. Clin Cancer Res. 2009, 15:3023-8.
7. Ruano Y, Ribalta T, de Lope AR. Worse outcome in primary glioblastoma multiforme with concurrent epidermal growth factor receptor and p53 alteration. Am J Clin Pathol. 2009, 131:257-63.
8. Cappuzzo F, Finocchiaro G, Rossi E. EGFR FISH assay predicts for response to cetuximab in chemotherapy refractory colorectal cancer patients. Ann Oncol. 2008, 19:717-23.
9. Ensinger C, Sterlacci W. Implications of EGFR PharmDx kit for cetuximab eligibility. Expert Rev Mol Diagn. 2008, 8:141-8.
10. Galizia G, Lieto E, Ferraraccio F. Prognostic significance of epidermal growth factor receptor expression in colon cancer patients undergoing curative surgery. Ann Surg Oncol. 2006, 13:823-35.
11. Goldstein NS, Armin M. Epidermal growth factor receptor immunohistochemical reactivity in patients with American Joint Committee on Cancer Stage IV colon adenocarcinoma: implications for a standardized scoring system. Cancer. 2001, 92:1331-46.
12. Lievre A, Bachet JB, Boige V. KRAS mutations as an independent prognostic factor in patients with advanced colorectal cancer treated with cetuximab. J Clin Oncol. 2008, 26:374-9.
13. Lievre A, Bachet JB, Le Corre D. KRAS mutation status is predictive of response to cetuximab therapy in colorectal cancer. Cancer Res. 2006, 66:3992-5.
14. Chiang KC, Chen TW, Yeh CN. Advanced gastrointestinal stromal tumor patients with complete response after treatment with imatinib mesylate. World J Gastroenterol. 2006, 12:2060-4.
15. Hirano D, Okada Y, Minei S. Neuroendocrine differentiation in hormone refractory prostate cancer following androgen deprivation therapy. Eur Urol. 2004, 45:586-92.
16. Lasota J, Miettinen M. Clinical significance of oncogenic KIT and PDGFRA mutations in gastrointestinal stromal tumours. Histopathology. 2008, 53:245-66.
17. Giles FJ, DeAngelo DJ, Baccarani M. Optimizing outcomes for patients with advanced disease in chronic myelogenous leukemia. Semin Oncol. 2008, 35:S1-17.
18. Fabian MA, Biggs WH, DK Treiber. A small molecule-kinase interaction map for clinical kinase inhibitors. Nat Biotechnol. 2005, 23:329-36.
19. Karaman MW, Herrgard S, Treiber DK. A quantitative analysis of kinase inhibitor selectivity. Nat Biotechnol. 2008, 26:127-32.
20. Miyazawa M, Yasuda M, Fujita M. Therapeutic strategy targeting the mTOR-HIF-1alpha-VEGF pathway in ovarian clear cell adenocarcinoma. Pathol Int. 2009, 59:19-27.
21. Yu G, Wang J, Chen Y. Overexpression of phosphorylated mammalian target of rapamycin predicts lymph node metastasis and prognosis of chinese patients with gastric cancer. Clin Cancer Res. 2009, 15:1821-9.
22. Umemura S, Yoshida S, Ohta Y. Increased phosphorylation of Akt in triple-negative breast cancers. Cancer Sci. 2007, 98:1889-92.
23. Bhatia S, Thompson JA. Temsirolimus in patients with advanced renal cell carcinoma: an overview. Adv Ther. 2009, 26:55-67.
24. Campbell L, Jasani B, Edwards K. Combined expression of caveolin-1 and an activated AKT/mTOR pathway predicts reduced disease-free survival in clinically confined renal cell carcinoma. Br J Cancer. 2008, 98:931-40.
25. Le Tourneau C, Faivre S, Serova M. mTORC1 inhibitors: is temsirolimus in renal cancer telling us how they really work. Br J Cancer. 2008, 99:1197-203.
26. Wysocki PJ. mTOR in renal cell cancer: modulator of tumor biology and therapeutic target. Expert Rev Mol Diagn. 2009, 9:231-41.
27. Kloppel G, Perren A, Heitz PU. The gastroenteropancreatic neuroendocrine cell system and its tumors: the WHO classification. Ann N Y Acad Sci. 2004, 1014:13-27.
28. Kulaksiz H, Eissele R, Rossler D. Identification of somatostatin receptor subtypes 1, 2A, 3, and 5 in neuroendocrine tumours with subtype specific antibodies. Gut. 2002, 50:52-60.
29. Modlin IM, Oberg K, Chung DC. Gastroenteropancreatic neuroendocrine tumours. Lancet Oncol. 2008, 9:61-72.
30. Rindi G, Kloppel G, Alhman H. TNM staging of foregut (neuro)endocrine tumors: a consensus proposal including a grading system. Virchows Arch. 2006, 449:395-401.
31. Rindi G, Kloppel G, Couvelard A. TNM staging of midgut and hindgut (neuro) endocrine tumors: a consensus proposal including a grading system. Virchows Arch. 2007, 451:757-62.
32. Nasir A, Stridsberg M, Strosberg J. Somatostatin receptor profiling in hepatic metastases from small intestinal and pancreatic neuroendocrine neoplasms: immunohistochemical approach with potential clinical utility. Cancer Control. 2006, 13:52-60.
33. Oberg K, Kvols L, Caplin M. Consensus report on the use of somatostatin analogs for the management of neuroendocrine tumors of the gastroenteropancreatic system. Ann Oncol. 2004, 15:966-73.